Compounds > tbe 31
Page last updated: 2024-11-12

tbe 31

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID16202704
CHEMBL ID224752
SCHEMBL ID8208843
MeSH IDM0525492

Synonyms (9)

Synonym
bdbm50096347
CHEMBL224752 ,
tbe-31
SCHEMBL8208843
[(+/-)-(4bs,8ar,10as)-10a-ethynyl-4b,8,8-trimethyl-3,7-dioxo-3,4b,7,8,8a,9,10,10a-octahydrophenanthrene-2,6-dicarbonitrile]
936475-62-6
(4bs,8ar,10as)-10a-ethynyl-4b,8,8-trimethyl-3,7-dioxo-9,10-dihydro-8ah-phenanthrene-2,6-dicarbonitrile
AKOS040749620
PD138831
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Nitric oxide synthase, inducibleMus musculus (house mouse)IC50 (µMol)0.00100.00103.39119.6000AID1226966
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Nuclear factor erythroid 2-related factor 2Mus musculus (house mouse)CD0.00090.00090.12580.3000AID1226965
NAD(P)H dehydrogenase [quinone] 1Mus musculus (house mouse)CD0.00150.00020.23892.6500AID589398; AID773676
Kelch-like ECH-associated protein 1Mus musculus (house mouse)CD0.00090.00090.06770.2000AID1226965
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
nucleoplasmNuclear factor erythroid 2-related factor 2Mus musculus (house mouse)
cytoplasmNuclear factor erythroid 2-related factor 2Mus musculus (house mouse)
cytosolNuclear factor erythroid 2-related factor 2Mus musculus (house mouse)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (28)

Assay IDTitleYearJournalArticle
AID589397Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of IFN-gamma induced NO production after 24 hrs by Griess reaction2011Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6
Tricyclic compounds containing nonenolizable cyano enones. A novel class of highly potent anti-inflammatory and cytoprotective agents.
AID589407Antitumor activity against aflatoxin B1-induced tumorigenesis in F344 rat liver assessed as reduction in tumor burden at 30 umol/kg administered via gavage2011Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6
Tricyclic compounds containing nonenolizable cyano enones. A novel class of highly potent anti-inflammatory and cytoprotective agents.
AID773676Induction of NQO1 activity in mouse Hepa1c1c7 cells assessed as concentration required to double specific enzyme activity after 48 hrs2013Bioorganic & medicinal chemistry letters, Oct-15, Volume: 23, Issue:20
Synthesis and biological evaluation of biotin conjugates of (±)-(4bS,8aR,10aS)-10a-ethynyl-4b,8,8-trimethyl-3,7-dioxo-3,4b,7,8,8a,9,10,10a-octahydro-phenanthrene-2,6-dicarbonitrile, an activator of the Keap1/Nrf2/ARE pathway, for the isolation of its prot
AID1226965Activation of Keap1/Nrf2/ARE pathway in mouse Hepa-1c1c7 cells assessed as double induction of NQO1 specific activity after 48 hrs by bicinchoninic acid assay2015Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11
New Monocyclic, Bicyclic, and Tricyclic Ethynylcyanodienones as Activators of the Keap1/Nrf2/ARE Pathway and Inhibitors of Inducible Nitric Oxide Synthase.
AID589404Induction of HO-1 expression in mouse RAW264.7 cells at 100 nM after 6 hrs by Western blotting2011Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6
Tricyclic compounds containing nonenolizable cyano enones. A novel class of highly potent anti-inflammatory and cytoprotective agents.
AID589401Induction of HO-1 expression in mouse RAW264.7 cells at 30 nM after 6 hrs by Western blotting2011Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6
Tricyclic compounds containing nonenolizable cyano enones. A novel class of highly potent anti-inflammatory and cytoprotective agents.
AID1226966Inhibition of iNOS in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of nitric oxide production after 48 hrs by Griess assay2015Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11
New Monocyclic, Bicyclic, and Tricyclic Ethynylcyanodienones as Activators of the Keap1/Nrf2/ARE Pathway and Inhibitors of Inducible Nitric Oxide Synthase.
AID676574Induction of apoptosis in LPS-stimulated C57BL/6 mouse BMDM cells assessed as LDH release at 0.1 uM pretreated for 1 hr before LPS challenge after 8 hrs2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Synthesis, chemical reactivity as Michael acceptors, and biological potency of monocyclic cyanoenones, novel and highly potent anti-inflammatory and cytoprotective agents.
AID589416Toxicity in F344 rat assessed as growth rate at 0.3 to 60 umol administered via gavage2011Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6
Tricyclic compounds containing nonenolizable cyano enones. A novel class of highly potent anti-inflammatory and cytoprotective agents.
AID589415Ratio of CDDO IC50 to compound IC50 for inhibition of IFN-gamma induced NO production in mouse RAW264.7 cells2011Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6
Tricyclic compounds containing nonenolizable cyano enones. A novel class of highly potent anti-inflammatory and cytoprotective agents.
AID589410Antitumor activity against aflatoxin B1-induced tumorigenesis in F344 rat liver assessed as reduction in tumor burden at 10 umol/kg administered via gavage relative to control2011Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6
Tricyclic compounds containing nonenolizable cyano enones. A novel class of highly potent anti-inflammatory and cytoprotective agents.
AID1636817Activation of Nrf2 in mouse Hepa-1c1c7 cells assessed as concentration required to double specific activity of NQO1 incubated for 48 hrs2016Bioorganic & medicinal chemistry letters, 09-01, Volume: 26, Issue:17
Electron affinity of tricyclic, bicyclic, and monocyclic compounds containing cyanoenones correlates with their potency as inducers of a cytoprotective enzyme.
AID281330Induction of HO1 in CD1 mouse stomach at 1 umol, po after 6 hrs2007Journal of medicinal chemistry, Apr-19, Volume: 50, Issue:8
Novel tricyclic compounds having acetylene groups at C-8a and cyano enones in rings A and C: highly potent anti-inflammatory and cytoprotective agents.
AID589398Induction of NQO1 activity in in mouse Hepa-1c1c7 cells after 48 hrs2011Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6
Tricyclic compounds containing nonenolizable cyano enones. A novel class of highly potent anti-inflammatory and cytoprotective agents.
AID589402Induction of HO-1 expression in mouse RAW264.7 cells at 300 nM after 6 hrs by Western blotting2011Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6
Tricyclic compounds containing nonenolizable cyano enones. A novel class of highly potent anti-inflammatory and cytoprotective agents.
AID281328Inhibition of interferon gamma-stimulated NO production in RAW 264.7 cells after 24 hrs2007Journal of medicinal chemistry, Apr-19, Volume: 50, Issue:8
Novel tricyclic compounds having acetylene groups at C-8a and cyano enones in rings A and C: highly potent anti-inflammatory and cytoprotective agents.
AID589403Induction of HO-1 expression in mouse RAW264.7 cells at 10 nM after 6 hrs by Western blotting2011Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6
Tricyclic compounds containing nonenolizable cyano enones. A novel class of highly potent anti-inflammatory and cytoprotective agents.
AID676570Antiinflammatory activity in C57BL/6 mouse BMDM cells assessed as inhibition of LPS-stimulated TNFalpha production at 0.1 uM pretreated for 1 hr before LPS challenge after 8 to 24 hrs by immunoassay2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Synthesis, chemical reactivity as Michael acceptors, and biological potency of monocyclic cyanoenones, novel and highly potent anti-inflammatory and cytoprotective agents.
AID589411Antitumor activity against aflatoxin B1-induced tumorigenesis in F344 rat liver assessed as inhibition of preneoplastic foci formation administered via gavage2011Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6
Tricyclic compounds containing nonenolizable cyano enones. A novel class of highly potent anti-inflammatory and cytoprotective agents.
AID589409Antitumor activity against aflatoxin B1-induced tumorigenesis in F344 rat liver assessed as reduction in tumor burden at 0.3 umol/kg administered via gavage relative to control2011Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6
Tricyclic compounds containing nonenolizable cyano enones. A novel class of highly potent anti-inflammatory and cytoprotective agents.
AID589399Inhibition of IFN-gamma induced iNOS expression in mouse RAW264.7 cells at 30 nM after 24 hrs by Western blotting2011Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6
Tricyclic compounds containing nonenolizable cyano enones. A novel class of highly potent anti-inflammatory and cytoprotective agents.
AID589408Antitumor activity against aflatoxin B1-induced tumorigenesis in F344 rat liver assessed as reduction in tumor burden at 60 umol/kg administered via gavage2011Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6
Tricyclic compounds containing nonenolizable cyano enones. A novel class of highly potent anti-inflammatory and cytoprotective agents.
AID589414Ratio of CDDO IC50 to compound IC50 for inhibition of IFN-gamma induced NO production in mouse macrophages2011Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6
Tricyclic compounds containing nonenolizable cyano enones. A novel class of highly potent anti-inflammatory and cytoprotective agents.
AID589406Induction of HO-1 expression in CD-1 mouse stomach at 1 umol administered via gavage measured after 6 hrs by Western blotting2011Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6
Tricyclic compounds containing nonenolizable cyano enones. A novel class of highly potent anti-inflammatory and cytoprotective agents.
AID676568Cytotoxicity against C57BL/6 mouse BMDM cells assessed as LDH release after 24 hrs2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Synthesis, chemical reactivity as Michael acceptors, and biological potency of monocyclic cyanoenones, novel and highly potent anti-inflammatory and cytoprotective agents.
AID589396Antiinflammatory activity in CD-1 mouse Macrophage assessed as inhibition of IFN-gamma induced NO production after 48 hrs by Griess reaction2011Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6
Tricyclic compounds containing nonenolizable cyano enones. A novel class of highly potent anti-inflammatory and cytoprotective agents.
AID589477Toxicity in F344 rat assessed as effect on body weight at 0.3 to 60 umol administered via gavage2011Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6
Tricyclic compounds containing nonenolizable cyano enones. A novel class of highly potent anti-inflammatory and cytoprotective agents.
AID281329Induction of HO1 in CD1 mouse liver at at 1 umol, po after 6 hrs2007Journal of medicinal chemistry, Apr-19, Volume: 50, Issue:8
Novel tricyclic compounds having acetylene groups at C-8a and cyano enones in rings A and C: highly potent anti-inflammatory and cytoprotective agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's5 (83.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 13.26

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index13.26 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index5.21 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (13.26)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
sulforaphane
sulforaphane: from Cardaria draba L.. sulforaphane : An isothiocyanate having a 4-(methylsulfinyl)butyl group attached to the nitrogen.		2.1110isothiocyanate;
sulfoxide		antineoplastic agent;
antioxidant;
EC 3.5.1.98 (histone deacetylase) inhibitor;
plant metabolite
Bardoxolone
[no description available]		2.9840cyclohexenones
bardoxolone methyl
methyl 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oate: structure in first source		2.4720cyclohexenones
2-((aminocarbonyl)amino)-5-(4-fluorophenyl)-3-thiophenecarboxamide
2-((aminocarbonyl)amino)-5-(4-fluorophenyl)-3-thiophenecarboxamide: an IKK-2 kinase inhibitor; structure in first source		2.0710aromatic amide;
thiophenes
1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole
[no description available]		2.4520
ConditionIndicatedRelationship StrengthStudiesTrials
Experimental Hepatoma
[description not available]		02.0610
Condition, Preneoplastic
[description not available]		02.0610
Precancerous Conditions
Pathological conditions that tend eventually to become malignant.		02.0610
Hepatocellular Carcinoma
[description not available]		02.1110
Innate Inflammatory Response
[description not available]		02.1110
Cancer of Liver
[description not available]		02.1110
Carcinoma, Hepatocellular
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.		02.1110
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.1110
Liver Neoplasms
Tumors or cancer of the LIVER.		02.1110